Ask AI
2025 Congress to Clinic Insights in Diabetes

CME

Global Perspectives on New Data in Type 2 Diabetes — Congress-to-Clinic Insights From ADA and EASD 2025

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 22, 2025

Expiration: October 21, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 62-yr-old patient with T2D (A1C 8.6%), obesity (BMI 38 kg/m2), and a history of ASCVD is currently on metformin and oral semaglutide. He is concerned about his ability to keep up with daily injections. Based on recent data, which emerging therapeutic option would likely be most beneficial for this patient?

2.

In the recent REDEFINE trials, cagrilintide + semaglutide demonstrated which of the following cardiometabolic outcomes?

3.

A patient with T2D (A1C 7.9%), obesity (BMI 42 kg/m2), and ASCVD is taking metformin and sitagliptin. The patient would like to focus on weight loss. Based on recent data, which emerging therapeutic option would likely be most beneficial for this patient?

4.

I am familiar with data from ADA 2025 and EASD 2025, and I plan to translate these data into current or future strategies.